Frequency Therapeutics Inc. is a United States-based clinical-stage progenitor cell activation (PCA) regeneration company. The Company is focused on developing small molecule drugs that activate progenitor cells within the body to restore healthy tissue. It uses its PCA technology to develop a pipeline of progenitor cell activators. It focuses on various therapeutic areas, such as hearing loss, skin disorders, muscle regeneration, and gastrointestinal diseases. Its lead program, FX-322, activates the regrowth of sensory cells in the inner ear to treat chronic noise induced hearing loss.